Skyler B. Johnson
( out of 172 reviews )

Skyler B. Johnson, MD

Languages spoken: English

Clinical Locations

Farmington Health Center

Farmington
801-213-3200

Huntsman Cancer Institute - Cancer Hospital South

Radiation Oncology
Salt Lake City
801-581-2396

  • Skyler Johnson, MD is an Assistant Professor in the Department of Radiation Oncology at the University of Utah Huntsman Cancer Institute. As a physician and researcher, he has sought to improve the lives of both individuals and the community through exemplary care and expertise in the area of health services research. His clinical specialties include prostate cancer and other genitourinary malignancies as well as gastrointestinal malignancies, lung cancer, and lymphoma. His research interests include comparative effectiveness, patient communication, patient education, clinical outcomes, quality of life research, cost-effectiveness, decision analyses, and clinical trial design.

    Dr. Johnson's research interests and passion for cancer care began during medical school at Michigan State University. He then completed a year-long research fellowship at the University of Michigan in the Department of Radiation Oncology. He completed his residency in radiation oncology at Yale, where he served as Chief Resident. While at Yale, he received additional training as a Health Sciences Research Fellow as part of the Yale National Clinical Scholars Program (NCSP) and a member of the Cancer Outcomes, Public Policy and Effectiveness Research Center (COPPER) group.

    His prior comparative effectiveness research on the use of non-traditional cancer treatments garnered national and international media attention from the lay press and resulted in over 450 news stories. He and members of his research team conducted television, radio, and print interviews with NBC, CNN, NPR, BBC, TIME Magazine, Reader's Digest, among others, and it was also prominently featured in the New York Times. More importantly, the research addressed an unmet need in the oncology medical literature and has been used in health policy documents including the WHO's report on cancer. This research has led to ongoing studies in collaboration with national cancer experts quantifying misinformation and potential for harm contained within cancer articles on social media, accuracy of cancer information using AI chatbots, as well as a multi-institutional study identifying sources of exposure, motivations, and perceptions of complementary and alternative medicine use in cancer. Dr. Johnson continually seeks to improve patient care and patient-physician communication by serving as Chair of the Huntsman Cancer Institute's Genitourinary Cancer Centers Communications and Community Outreach Committee as well as being a member of the NRG Oncology New Investigator Committee and American Society for Radiation Oncology’s (ASTRO) Communications Committee. He is an internationally recognized expert on cancer misinformation, its impacts, and potential solutions, frequently delivering invited lectures at prestigious institutions across the country and participating in multi-institutional forums on health mis- and disinformation.

    Specialties

    Board Certification

    American Board of Radiology (Radiation Oncology)

    Patient Rating

    5.0 /5
    ( out of 172 reviews )

    The patient rating score is an average of all responses on our patient experience survey. The rating averages scores for all questions about care from our providers.

    The scale on which responses are measured is 1 to 5 with 5 being the best score.

    Patient Comments

    Patient comments are gathered from our patient experience survey and displayed in their entirety.
    Patients are de-identified for confidentiality and patient privacy.

    September 27, 2024
    FARMINGTON HEALTH CENTER

    Excellent bedside manner

    September 23, 2024
    FARMINGTON HEALTH CENTER

    You feel comfortable talking with him. He makes the time for you.

    September 18, 2024
    HUNTSMAN CANCER CENTER

    Dr. Johnson is a great doctor who is personable and honest about the future of our care! He is understanding and explains everything clearly. He is the best!

    September 05, 2024
    FARMINGTON HEALTH CENTER

    Dr. Johnson is very kind and takes the time to find out how I'm doing and offer suggestions.

    July 31, 2024
    HUNTSMAN CANCER CENTER

    Dr Johnson is a very knowledgeable Dr. he takes his time to make sure you understand everything that is being done and makes sure all of your questions are answered.

    July 27, 2024
    FARMINGTON HEALTH CENTER

    Very professional and explained the procedure so I could understand.

    July 25, 2024
    HUNTSMAN CANCER CENTER

    Dr. Johnson's care is second-to-none! This good man has always taken good care of me and has been willing to listen and research suggestions. I trust him 100% with my health!

    July 15, 2024
    HUNTSMAN CANCER CENTER

    Dr. Johnson is the best!

    July 14, 2024
    HUNTSMAN CANCER CENTER

    He's just a very nice guy. He knows what he's talking about

    See More Patient Comments

  • Skyler Johnson, MD is an Assistant Professor in the Department of Radiation Oncology at the University of Utah Huntsman Cancer Institute. As a physician and researcher, he has sought to improve the lives of both individuals and the community through exemplary care and expertise in the area of health services research. His clinical specialties include prostate cancer and other genitourinary malignancies as well as gastrointestinal malignancies, lung cancer, and lymphoma. His research interests include comparative effectiveness, patient communication, patient education, clinical outcomes, quality of life research, cost-effectiveness, decision analyses, and clinical trial design.

    Dr. Johnson's research interests and passion for cancer care began during medical school at Michigan State University. He then completed a year-long research fellowship at the University of Michigan in the Department of Radiation Oncology. He completed his residency in radiation oncology at Yale, where he served as Chief Resident. While at Yale, he received additional training as a Health Sciences Research Fellow as part of the Yale National Clinical Scholars Program (NCSP) and a member of the Cancer Outcomes, Public Policy and Effectiveness Research Center (COPPER) group.

    His prior comparative effectiveness research on the use of non-traditional cancer treatments garnered national and international media attention from the lay press and resulted in over 450 news stories. He and members of his research team conducted television, radio, and print interviews with NBC, CNN, NPR, BBC, TIME Magazine, Reader's Digest, among others, and it was also prominently featured in the New York Times. More importantly, the research addressed an unmet need in the oncology medical literature and has been used in health policy documents including the WHO's report on cancer. This research has led to ongoing studies in collaboration with national cancer experts quantifying misinformation and potential for harm contained within cancer articles on social media, accuracy of cancer information using AI chatbots, as well as a multi-institutional study identifying sources of exposure, motivations, and perceptions of complementary and alternative medicine use in cancer. Dr. Johnson continually seeks to improve patient care and patient-physician communication by serving as Chair of the Huntsman Cancer Institute's Genitourinary Cancer Centers Communications and Community Outreach Committee as well as being a member of the NRG Oncology New Investigator Committee and American Society for Radiation Oncology’s (ASTRO) Communications Committee. He is an internationally recognized expert on cancer misinformation, its impacts, and potential solutions, frequently delivering invited lectures at prestigious institutions across the country and participating in multi-institutional forums on health mis- and disinformation.

    Board Certification and Academic Information

    Academic Departments Radiation Oncology -Primary
    Board Certification
    American Board of Radiology (Radiation Oncology)

    Education history

    Certification Clinical Educator, Teaching and Learning Center - Yale School of Medicine, New Haven, CT Certification
    Radiation Oncology - Yale School of Medicine, New Haven, CT Chief Resident
    Research Fellow National Clinician Scholars Program - Yale School of Medicine, New Haven, CT Research Fellow
    Radiation Oncology - Yale School of Medicine, New Haven, CT Resident
    Internship Internal Medicine - Beaumont Health, Oakwood Hospital, Dearborn, MI Intern
    Medicine - Michigan State University College of Human Medicine, East Lansing, MI M.D.
    Undergraduate Major: Zoology; Minor: Chemistry - Weber State University, Ogden, UT B.S.

    Selected Publications

    Journal Article

    1. Mullis MD, Fisher CL, Johnson SB, Liu T, Amin TB, Rogers S, DeGruccio K, Bylund CL (2024). Clinician-patient communication about cancer treatment misinformation: The Misinformation Response Model. PEC Innov, 5. (Read full article)
    2. Bylund CL, Taylor G, Vasquez TS, Alpert J, Johnson SB, Le T, Paige SR, Close J, Markham MJ (2024). Talking with clinicians about online cancer information: a survey of cancer patients and surrogate information seekers. Support Care Cancer, 32(6), 362. (Read full article)
    3. Roach E, Hutten R, Johnson S, Suneja G, Tward J, Petereit D, Gaffney D (2024). The impact of a positive COVID-19 test on timeliness of radiation in patients receiving brachytherapy. Brachytherapy, 23(3), 360-367. (Read full article)
    4. Hutten RJ, Odei B, Johnson SB, Tward JD (2024). Validation of the Combined Clinical Cell-Cycle Risk Score to Prognosticate Early Prostate Cancer Metastasis From Biopsy Specimens and Comparison With Other Routinely Used Risk Classifiers. JCO Precis Oncol, 8, e2300364. (Read full article)
    5. Hutten RJ, Weil CR, King AJ, Barney B, Bylund CL, Fagerlin A, Gaffney DK, Gill D, Scherer L, Suneja G, Tward JD, Warner EL, Werner TL, Whipple G, Evans J, Johnson SB (2023). Multi-Institutional Analysis of Cancer Patient Exposure, Perceptions, and Trust in Information Sources Regarding Complementary and Alternative Medicine. JCO Oncol Pract, 19(11), 1000-1008. (Read full article)
    6. Fridman I, Johnson S, Elston Lafata J (2023). Health Information and Misinformation: A Framework to Guide Research and Practice. JMIR Med Educ, 9, e38687. (Read full article)
    7. Johnson SB, King AJ, Warner EL, Aneja S, Kann BH, Bylund CL (2023). Using ChatGPT to evaluate cancer myths and misconceptions: artificial intelligence and cancer information. JNCI Cancer Spectr, 7(2). (Read full article)
    8. Johnson SB, King AJ, Warner EL, Aneja S, Kann BH, Bylund CL (2023). Using ChatGPT to evaluate cancer myths and misconceptions: artificial intelligence and cancer information. JNCI Cancer Spectr, 7(2). (Read full article)
    9. Johnson SB, Bylund CL (2023). Identifying Cancer Treatment Misinformation and Strategies to Mitigate Its Effects With Improved Radiation Oncologist-Patient Communication. Pract Radiat Oncol. (Read full article)
    10. Peterson J, Wilson TF, Watt MH, Gruhl J, Davis S, Olsen J, Parsons MW, Kann BH, Swire-Thompson B, Fagerlin A, Warner EL, King AJ, Chino F, Johnson SB (2023). International medical tourism of US cancer patients for alternative cancer treatments: Financial, demographic, and clinical profiles of online crowdfunding campaigns. Cancer Med, 12(7), 8871-8879. (Read full article)
    11. Bylund CL, Mullis MD, Alpert J, Markham MJ, Onega T, Fisher CL, Johnson SB (2023). Clinician Communication With Patients About Cancer Misinformation: A Qualitative Study. JCO Oncol Pract, OP2200526. (Read full article)
    12. Fridman I, Johnson S, Elston Lafata J (2023). Health Information and Misinformation: A Framework to Guide Research and Practice. JMIR Med Educ, 9. (Read full article)
    13. Fenlon JB, Hutten RJ, Johnson SB, Hu B, Shah H, Stephens DM, Maity A, Gaffney DK, Tao R (2022). Evaluating patterns of care for early-stage low-grade follicular lymphoma in the rituximab era. Leuk Lymphoma, 64(2), 1-8. (Read full article)
    14. Peterson JS, Plana D, Bitterman DS, Johnson SB, Aerts HJWL, Kann BH (2022). Growth in eligibility criteria content and failure to accrue among National Cancer Institute (NCI)-affiliated clinical trials. Cancer Med. (Read full article)
    15. Seymour ZA, Daignault-Newton S, McLaughlin PW, Sandler H, Jackson W, Johnson SB, Miller D, Wei J, Sanda M, Hamstra DA (2022). Patient reported outcomes for quality of life (QOL) by Expanded Prostate Cancer Index (EPIC) on average 15 years post treatment. Clin Transl Radiat Oncol, 36, 56-62. (Read full article)
    16. Hutten RJ, Nelson G, Sarkar V, Johnson SB, Tao R, Hitchcock Y, Chan J, Schroeder J, Kokeny K (2022). Feasibility and clinical utility of a workflow interfacing radiation oncology lung stereotactic body radiotherapy treatment planning and diagnostic radiology. Pract Radiat Oncol, 12(6), e512-e516. (Read full article)
    17. Hutten R, Khouri A, Parsons M, Tward A, Wilson T, Peterson J, Morrell G, Dechet C, ONeil B, Schmidt B, Kokeny K, Lloyd S, Cannon D, Tward J, Sanchez A, Johnson S (2022). The Clinical Significance of Maximum Tumor Diameter on MRI in Men Undergoing Radical Prostatectomy or Definitive Radiotherapy for Locoregional Prostate Cancer. Clin Genitourin Cancer, 20(6), e453-e459. (Read full article)
    18. Peterson J, Wilson T, Gruhl J, Davis S, Olsen J, Parsons M, Kann B, Fagerlin A, Watt M, Johnson S (2022). Timing and Motivations for Alternative Cancer Therapy With Insights From a Crowdfunding Platform: Cross-sectional Mixed Methods Study. JMIR Cancer, 8(2), e34183. (Read full article)
    19. Seymour ZA, Daignault-Newton S, McLaughlin PW, Sandler H, Jackson W, Johnson SB, Miller D, Wei J, Sanda M, Hamstra DA (2022). Patient reported outcomes for quality of life (QOL) by Expanded Prostate Cancer Index (EPIC) on average 15 years post treatment. Clin Transl Radiat Oncol, 36, 56-62. (Read full article)
    20. Parsons M, Lloyd S, Johnson S, Scaife C, Soares H, Kim R, Kim R, Garrido-Laguna I, Tao R (2022). The Implications of Treatment Delays in Adjuvant Therapy for Resected Cholangiocarcinoma Patients. J Gastrointest Cancer, 1-9. (Read full article)
    21. Peterson J, Wilson T, Gruhl J, Davis S, Olsen J, Parsons M, Kann B, Fagerlin A, Watt M, Johnson S (2022). Timing and Motivations for Alternative Cancer Therapy with Insights from a Crowdfunding Platform: Cross-sectional Mixed Methods Study. JMIR Cancer, 8(2). (Read full article)
    22. Parsons MW, Hutten RJ, Tward A, Khouri A, Peterson J, Morrell G, Lloyd S, Cannon DM, Johnson SB (2021). The Effect of Maximum Tumor Diameter by MRI on Disease Control in Intermediate and High-risk Prostate Cancer Patients Treated With Brachytherapy Boost. Clin Genitourin Cancer, 20(1), e68-e74. (Read full article)
    23. Weil CR, Parsons MJ, Hutten RJ, Lew FH, Johnson SB, Gaffney DK, Tao R (2022). Patterns of care and outcomes of early stage I–II Hodgkin lymphoma treated with or without radiation therapy. Leuk Lymphoma. (Read full article)
    24. Parsons M, Lloyd S, Johnson S, Scaife C, Soares H, Kim R, Kim R, Garrido-Laguna I, Tao R (2022). The Implications of Treatment Delays in Adjuvant Therapy for Resected Cholangiocarcinoma Patients. J Gastrointest Cancer. (Read full article)
    25. Hutten R, Khouri A, Parsons M, Tward A, Wilson T, Peterson J, Morrell G, Dechet C, ONeil B, Schmidt B, Kokeny K, Lloyd S, Cannon D, Tward J, Sanchez A, Johnson S (2022). The Clinical Significance of Maximum Tumor Diameter on MRI in Men Undergoing Radical Prostatectomy or Definitive Radiotherapy for Locoregional Prostate Cancer. Clin Genitourin Cancer. (Read full article)
    26. Hutten RJ, Parsons MW, Weil CR, Tward JD, Lloyd S, Sanchez A, Lester-Coll N, Johnson SB (2021). Temporal Trends and Predictors in Diagnosing Pathologic Node-Positive Prostate Cancer in Clinically Node-Negative Patients. Clin Genitourin Cancer, 19(6), e360-e366. (Read full article)
    27. Johnson SB, Parsons M, Dorff T, Moran MS, Ward JH, Cohen SA, Akerley W, Bauman J, Hubbard J, Spratt DE, Bylund CL, Swire-Thompson B, Onega T, Scherer LD, Tward J, Fagerlin A (2021). Cancer Misinformation and Harmful Information on Facebook and Other Social Media: A Brief Report. J Natl Cancer Inst, 114, 1036-1039. (Read full article)
    28. Miccio JA, Talcott WJ, Jairam V, Park HS, Yu JB, Leapman MS, Johnson SB, King MT, Nguyen PL, Kann BH (2020). Quantifying treatment selection bias effect on survival in comparative effectiveness research: findings from low-risk prostate cancer patients. Prostate Cancer Prostatic Dis, 24(2), 414-422. (Read full article)
    29. Parsons M, Lloyd S, Johnson S, Scaife C, Varghese T, Glasgow R, Garrido-Laguna I, Tao R (2020). Refusal of Local Therapy in Esophageal Cancer and Impact on Overall Survival. Ann Surg Oncol, 28(2), 663-675. (Read full article)
    30. Hutten RJ, Weil CR, Tward JD, Lloyd S, Johnson SB (2021). Patterns of Care and Treatment Outcomes in Locoregional Squamous Cell Carcinoma of the Prostate. Eur Urol Open Sci, 23, 30-33. (Read full article)
    31. Joseph Anthony Miccio, MD Andrew Barsky, MD Sarah Gao, MD Vivek Verma, MD Sonal S Noticewala, MD, MAS Vikram Jairam, MD Skyler B Johnson, MD James B Yu, MD, MHS James E Hansen, MD Sanjay Aneja, MD Yi An, MD Roy H Decker, MD, PhD S Bulent Omay, MD Jing Li, MD, PhD Goldie A Kurtz, MD Michelle Alonso-Basanta, MD, PhD John YK Lee, MD Veronica Chiang, MD Henry S Park, MD, MPH (2020). Multi-Institutional Retrospective Review of Stereotactic Radiosurgery for Brain Metastasis in Patients with Small Cell Lung Cancer Without Prior Brain-Directed Radiotherapy. J Neurooncol.
    32. Cecchini M, Miccio JA, Pahade J, Lacy J, Salem RR, Johnson SB, Blakaj A, Stein S, Kortmansky JS, Johung KL (2020). A Single-Institution Experience of Induction 5-Fluorouracil, Leucovorin, Irinotecan, and Oxaliplatin Followed by Surgery Versus Consolidative Radiation for Borderline and Locally Advanced Unresectable Pancreatic Cancer. Pancreas, 49(7), 904-911. (Read full article)
    33. Benjamin H Kann, MD, Skyler B Johnson, MD, Hugo JWL Aerts, PhD, Raymond H Mak, MD, Paul L Nguyen, MD (2020). Changes in Length and Complexity of Clinical Practice Guidelines in Oncology, 1996-2019. JAMA Netw Open.
    34. Miccio JA, Barsky A, Gao S, Verma V, Noticewala SS, Jairam V, Johnson SB, Yu JB, Hansen JE, Aneja S, An Y, Decker RH, Omay SB, Li J, Kurtz GA, Alonso-Basanta M, Lee JYK, Chiang VL, Park HS (2020). Multi-institutional retrospective review of stereotactic radiosurgery for brain metastasis in patients with small-cell lung cancer without prior brain-directed radiotherapy. J Radiosurg SBRT, 7(1), 19-27. (Read full article)
    35. Miccio JA, Barsky A, Gao S, Verma V, Noticewala SS, Jairam V, Johnson SB, Yu JB, Hansen JE, Aneja S, An Y, Decker RH, Bulent Omay S, Li J, Kurtz GA, Alonso-Basanta M, Lee JYK, Chiang VL, Park HS (2020). Multi-institutional retrospective review of stereotactic radiosurgery for brain metastasis in patients with small cell lung cancer without prior brain-directed radiotherapy. J Radiosurg SBRT, 7(1), 19-27. (Read full article)
    36. Loganadane G, Kann BH, Park HS, Johnson SB, Mehra S, Judson BL, Bhatia A, Belkacemi Y, Yarbrough WG, Burtness B, Husain ZA (2019). Clinical Outcomes of Head and Neck Cancer Patients Who Undergo Resection, But Forgo Adjuvant Therapy. Anticancer Res, 39(9), 4885-4890. (Read full article)
    37. Kole AJ, Park HS, Johnson SB, Kelly JR, Moran MS, Patel AA (2019). Overall survival is improved when DCIS accompanies invasive breast cancer. Sci Rep, 9(1), 9934. (Read full article)
    38. Johnson S, Park H, Gross C, Yu J (2019). Complementary Medicine, Refusal of Conventional Cancer Therapy, and Survival among Patients with Curable Cancers. Obstet Gynecol Surv, 74(4), 217-219. (Read full article)
    39. Johnson SB, Gross CP, Yu JB (2019). Methodology Flaws and Implications of a Complementary Medicine Study-In Reply. JAMA Oncol, 5(3), 433. (Read full article)
    40. Johnson SB, Hung J, Kapadia N, Oh KS, Kim M, Hamstra DA (2019). Spinal Growth Patterns After Craniospinal Irradiation in Children With Medulloblastoma. Pract Radiat Oncol, 9(1), e22-e28. (Read full article)
    41. Johnson SB, Decker RH (2018). Prophylactic Cranial Irradiation Versus Surveillance: Physician Bias and Patient-centered Decision-making. Clin Lung Cancer, 19(6), 464-466. (Read full article)
    42. Johnson SB, Park HS, Gross CP, Yu JB (2018). Complementary Medicine, Refusal of Conventional Cancer Therapy, and Survival Among Patients With Curable Cancers. JAMA Oncol, 4(10), 1375-1381. (Read full article)
    43. Johnson SB, Yu JB (2018). Bladder Preserving Trimodality Therapy for Muscle-Invasive Bladder Cancer. Curr Oncol Rep, 20(9), 66. (Read full article)
    44. Johnson SB, Park HS, Gross CP, Yu JB (2018). Use of Alternative Medicine for Cancer and Its Impact on Survival. J Natl Cancer Inst, 110(1). (Read full article)
    45. Kann BH, Park HS, Johnson SB, Chiang VL, Yu JB (2017). Radiosurgery for Brain Metastases: Changing Practice Patterns and Disparities in the United States. J Natl Compr Canc Netw, 15(12), 1494-1502. (Read full article)
    46. Johnson SB, Lester-Coll NH, Kelly JR, Kann BH, Yu JB, Nath SK (2017). Brachytherapy Boost Utilization and Survival in Unfavorable-risk Prostate Cancer. Eur Urol, 72(5), 738-744. (Read full article)
    47. Lester-Coll NH, Johnson S, Magnuson WJ, Goldhaber SZ, Sher DJ, DAmico AV, Yu JB (2017). Weighing Risk of Cardiovascular Mortality Against Potential Benefit of Hormonal Therapy in Intermediate-Risk Prostate Cancer.LID - 10.1093/jnci/djw281 [doi]. J Natl Cancer Inst, 109(6). (Read full article)
    48. Johnson SB, Soulos PR, Shafman TD, Mantz CA, Dosoretz AP, Ross R, Finkelstein SE, Collins SP, Suy S, Brower JV, Ritter MA, King CR, Kupelian PA, Horwitz EM, Pollack A, Abramowitz MC, Hallman MA, Faria S, Gross CP, Yu JB (2016). Patient-reported quality of life after stereotactic body radiation therapy versus moderate hypofractionation for clinically localized prostate cancer. Radiother Oncol, 121(2), 294-298. (Read full article)
    49. Feng FY, Zhang Y, Kothari V, Evans JR, Jackson WC, Chen W, Johnson SB, Luczak C, Wang S, Hamstra DA (2016). MDM2 Inhibition Sensitizes Prostate Cancer Cells to Androgen Ablation and Radiotherapy in a p53-Dependent Manner. Neoplasia, 18(4), 213-22. (Read full article)
    50. Jackson WC, Schipper MJ, Johnson SB, Foster C, Li D, Sandler HM, Palapattu GS, Hamstra DA, Feng FY (2016). Duration of Androgen Deprivation Therapy Influences Outcomes for Patients Receiving Radiation Therapy Following Radical Prostatectomy. Eur Urol, 69(1), 50-7. (Read full article)
    51. Johnson SB, Jackson WC, Murgic J, Feng FY, Hamstra DA (2015). Time to Nadir PSA: Of Popes and PSA--The Immortality Bias. Am J Clin Oncol, 38(5), 465-71. (Read full article)
    52. Jackson WC, Johnson SB, Feng FY, Hamstra DA (2015 Aug). Salvage radiation therapy improves metastasis-free survival for clinically aggressive and indolent prostate cancer recurrences after radical prostatectomy. Am J Clin Oncol, 38(4), 367-72. (Read full article)
    53. Hamstra DA, Johnson SB, Daignault S, Zikmund-Fisher BJ, Taylor JM, Larkin K, Wood A, Fagerlin A (2015 Jan). The impact of numeracy on verbatim knowledge of the longitudinal risk for prostate cancer recurrence following radiation therapy. Med Decis Making, 35(1), 27-36. (Read full article)
    54. Foster CC, Jackson WC, Foster BC, Johnson SB, Feng FY, Hamstra DA (2014). Less advanced disease at initiation of salvage androgen deprivation therapy is associated with decreased mortality following biochemical failure post-salvage radiation therapy. Radiat Oncol, 9, 245. (Read full article)
    55. Johnson S, Jackson W, Speers C, Feng F, Hamstra D (2014). A comprehensive assessment of the prognostic utility of the Stephenson nomogram for salvage radiation therapy postprostatectomy. Pract Radiat Oncol, 4(6), 422-9. (Read full article)
    56. Johnson SB, Zhou J, Jolly S, Guo B, Young L, Prisciandaro JI (2014 May-Jun). The dosimetric impact of single, dual, and triple tandem applicators in the treatment of intact uterine cancer. Brachytherapy, 13(3), 268-74. (Read full article)
    57. Jackson WC, Johnson SB, Foster B, Foster C, Li D, Song Y, Vainshtein J, Zhou J, Hamstra DA, Feng FY (2014). Combining prostate-specific antigen nadir and time to nadir allows for early identification of patients at highest risk for development of metastasis and death following salvage radiation therapy. Pract Radiat Oncol, 4(2), 99-107. (Read full article)
    58. Stenmark MH, Conlon AS, Johnson S, Daignault S, Litzenberg D, Marsh R, Ritter T, Vance S, Kazzi N, Feng FY, Sandler H, Sanda MG, Hamstra DA (2014). Dose to the inferior rectum is strongly associated with patient reported bowel quality of life after radiation therapy for prostate cancer. Radiother Oncol, 110(2), 291-7. (Read full article)
    59. Johnson SB, Hamstra DA, Jackson WC, Zhou J, Foster B, Foster C, Song Y, Li D, Palapattu GS, Kunju L, Mehra R, Sandler H, Feng FY (2013 Oct 1). Larger maximum tumor diameter at radical prostatectomy is associated with increased biochemical failure, metastasis, and death from prostate cancer after salvage radiation for prostate cancer. Int J Radiat Oncol Biol Phys, 87(2), 275-81. (Read full article)
    60. Jackson W, Hamstra DA, Johnson S, Zhou J, Foster B, Foster C, Li D, Song Y, Palapattu GS, Kunju LP, Mehra R, Feng FY (2013). Gleason pattern 5 is the strongest pathologic predictor of recurrence, metastasis, and prostate cancer-specific death in patients receiving salvage radiation therapy following radical prostatectomy. Cancer, 119(18), 3287-94. (Read full article)
    61. Jackson WC, Johnson SB, Li D, Foster C, Foster B, Song Y, Schipper M, Shilkrut M, Sandler HM, Morgan TM, Palapattu GS, Hamstra DA, Feng FY (2013 Jul 8). A prostate-specific antigen doubling time of <6 months is prognostic for metastasis and prostate cancer-specific death for patients receiving salvage radiation therapy post radical prostatectomy. Radiat Oncol, 8, 170. (Read full article)
    62. Johnson S, Jackson W, Li D, Song Y, Foster C, Foster B, Zhou J, Vainshtein J, Feng F, Hamstra D (2013). The interval to biochemical failure is prognostic for metastasis, prostate cancer-specific mortality, and overall mortality after salvage radiation therapy for prostate cancer. Int J Radiat Oncol Biol Phys, 86(3), 554-61. (Read full article)
    63. Hamstra DA, Stenmark MH, Ritter T, Litzenberg D, Jackson W, Johnson S, Albrecht-Unger L, Donaghy A, Phelps L, Blas K, Halverson S, Marsh R, Olson K, Feng FY (2013). Age and comorbid illness are associated with late rectal toxicity following dose-escalated radiation therapy for prostate cancer. Int J Radiat Oncol Biol Phys, 85(5), 1246-53. (Read full article)

    Review

    1. Swire-Thompson B, Johnson S (2024). Cancer: A model topic for misinformation researchers. [Review]. Curr Opin Psychol, 56. (Read full article)
    2. Ford KL, Orsso CE, Kiss N, Johnson SB, Purcell SA, Gagnon A, Laviano A, Prado CM (2022). Dietary choices after a cancer diagnosis: A narrative review. [Review]. Nutrition, 103-104, 111838. (Read full article)

    Book Chapter

    1. Johnson SB, Decker RH (2017). Radiation Therapy. In Ariyan SP, Kluger H (Eds.), The Melanoma Handbook (p. 157). Springer Publishing Company.
    2. Johnson SB, Damast S, Young M (2016). Cervical Cancer. In Chamberlain D, Decker RH, Yu JB (Eds.), Pocket Guide to Radiation Oncology. Springer Publishing Company.

    Case Report

    1. Johnson SB, Prisciandaro JI, Zhou J, Hadley SW, Reynolds RK, Jolly S (2014). Primary peritoneal clear cell carcinoma treated with IMRT and interstitial HDR brachytherapy: a case report. J Appl Clin Med Phys, 15(1), 4520. (Read full article)

    Editorial

    1. Peterson JS, Swire-Thompson B, Johnson SB (2020). What is the alternative? Responding strategically to cancer misinformation. Future Oncol, 16(25), 1883-1888. (Read full article)
    2. Johnson SB, Decker RH (Accepted). Prophylactic Cranial Irradiation Versus Surveillance:: Physician Bias in Prophylactic Cranial Irradiation (PCI) Decision Making-Opportunity for a Patient Decision Aid. Clin Lung Cancer.

    Letter

    1. Hutten RJ, Weil CR, Tward JD, Lloyd S, Johnson SB (2021). Patterns of Care and Treatment Outcomes in Locoregional Squamous Cell Carcinoma of the Prostate [Letter to the editor]. Eur Urol Open Sci, 23, 30-33. (Read full article)

  • News & Podcasts

    Huntsman Cancer Institute News